The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner
Abstract
Although p53 is not essential for normal embryonic development, it plays a pivotal role in many biological and pathological processes, including cell fate determination-dependent and independent events and diseases. The expression and activity of p53 largely depend on its two biological inhibitors, MDM2 and MDMX, which have been shown to form a complex in order to tightly control p53 to an undetectable level during early stages of embryonic development. However, more delicate studies using conditional gene-modification mouse models show that MDM2 and MDMX may function separately or synergistically on p53 regulation during later stages of embryonic development and adulthood in a cell and tissue-specific manner. Here, we report the role of the MDM2/MDMX-p53 pathway in pancreatic islet morphogenesis and functional maintenance, using mouse lines with specific deletion of MDM2 or MDMX in pancreatic endocrine progenitor cells. Interestingly, deletion of MDM2 results in defects of embryonic endocrine pancreas development, followed by neonatal hyperglycemia and lethality, by inducing pancreatic progenitor cell apoptosis and inhibiting cell proliferation. However, unlike MDM2-knockout animals, mice lacking MDMX in endocrine progenitor cells develop normally. But, surprisingly, the survival rate of adult MDMX-knockout mice drastically declines compared to control mice, as blockage of neonatal development of endocrine pancreas by inhibition of cell proliferation and subsequent islet dysfunction and hyperglycemia eventually lead to type 1 diabetes-like disease with advanced diabetic nephropathy. As expected, both MDM2 and MDMX deletion-caused pancreatic defects are completely rescued by loss of p53, verifying the crucial role of the MDM2 and/or MDMX in regulating p53 in a spatio-temporal manner during the development, functional maintenance, and related disease progress of endocrine pancreas. Also, our study suggests a possible mouse model of advanced diabetic nephropathy, which is complementary to other established diabetic models and perhaps useful for the development of anti-diabetes therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many studies have suggested that activated p53 induces the death of pancreatic β-cells in response to increased free fatty acid levels and oxidative stress.275–277”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [275]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 3×
“…developmental defects and adult diabetes phenotypes caused by conditional MDM2 and MDMX deletion, respectively As the most important target of MDM2 and MDMX, p53 activation nearly takes all the responsibility for the defects caused by MDM2 or MDMX deletion (Kruse and Gu, 2009; Wade et al., 2010).”
BackgroundMarino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
MicroRNA functions in stress responses
Leung, A. K. L., & Sharp, P. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.027 · Cited by 865 · cited 1×
“…transcription factor by monitoring cell cycle arrest, cell death, autophagy and senescence, through transactivation of many cell death and survival related protein-encoding genes, or other transcription-independent mechanisms (Boominathan, 2010; Lane and Levine, 2010) (Leung and Sharp, 2010).”
BackgroundSignaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
Self-citationAdipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Vona-Davis, L., & Rose, D. P. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0068 · Cited by 496 · cited 1×
“…serum level and local production of estrogens in adipose tissue (Cleary and Grossmann, 2009), endocrine/paracrine/autocrine-influence of adipokines (Vona-Davis and Rose, 2007), chronic systemic low-grade inflammation (Doyle et al., 2012), hypercholesterolemia (Nelson et al., 2013), and other…”
BackgroundThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Tersey, S. A., Nishiki, Y., Templin, A. T., Cabrera, S. M., Stull, N. D., Colvin, S. C., Evans-Molina, C., Rickus, J. L., Maier, B., & Mirmira, R. G. (2012) · Diabetes · doi:10.2337/db11-1293 · Cited by 353 · cited 1×
“…al., 2014; Ren et al., 2016; Yao et al., 2013), in both the trigger of β-cell autoimmunity during type 1 diabetes initiation (Padgett et al., 2013; Tersey et al., 2012) and the progression of type 2 diabetes (Asahara et al., 2009; Donath and Shoelson, 2011; Wellen and Hotamisligil, 2005), it is…”
BackgroundRecessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis
Garin, I., Edghill, E. L., Akerman, I., Rubio-Cabezas, O., Rica, I., Locke, J. M., Maestro, M. A., Alshaikh, A., Bundak, R., del Castillo, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910533107 · Cited by 211
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193 · cited 3×
“It has been indicated that MDM2 forms a complex with MDMX through their C-terminal RING domains to inhibit p53 during early embryogenesis (Huang et al., 2011; Pant et al., 2011).”
BackgroundSynergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Research works printed but not linked: 65
- Aguilar-Bryan, 2008, Neonatal diabetes mellitus, Endocr. Rev., 29, 265, 10.1210/er.2007-0029 · DOI · Paper page
- Allagnat, 2013, Connexin36 contributes to INS-1E cells survival through modulation of cytokine-induced oxidative stress, ER stress and AMPK activity, Cell Death Differ., 20, 1742, 10.1038/cdd.2013.134 · DOI
- Antoniali, 2014, Emerging roles of the nucleolus in regulating the DNA damage response: the noncanonical DNA repair enzyme APE1/Ref-1 as a paradigmatical example, Antioxid. Redox Signal, 20, 621, 10.1089/ars.2013.5491 · DOI
- Asahara, 2009, Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes, Biochem. Biophys. Res. Commun., 381, 367, 10.1016/j.bbrc.2009.02.047 · DOI
- Ashery-Padan, 2000, Pax6 activity in the lens primordium is required for lens formation and for correct placement of a single retina in the eye, Genes Dev., 14, 2701, 10.1101/gad.184000 · DOI · Paper page
- Ashery-Padan, 2004, Conditional inactivation of Pax6 in the pancreas causes early onset of diabetes, Dev. Biol., 269, 479, 10.1016/j.ydbio.2004.01.040 · DOI
- Betz, 2014, Recent advances in animal models of diabetic nephropathy. nephron, Exp. Nephrol., 126, 191, 10.1159/000363300 · doi:10.1159/000363300
- Betz, 2016, An update on the use of animal models in diabetic nephropathy research, Curr. Diabetes Rep., 16, 18, 10.1007/s11892-015-0706-2 · DOI
- Bitti, 2011, Genotypes of p53 codon 72 correlate with age at onset of type 1 diabetes in a sex-specific manner, J. Pediatr. Endocrinol. Metab., 24, 437, 10.1515/jpem.2011.058 · DOI
- Boominathan, 2010, The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network, Cancer Metastasis Rev., 29, 613, 10.1007/s10555-010-9257-9 · DOI
- Breyer, 2005, Mouse models of diabetic nephropathy, J. Am. Soc. Nephrol., 16, 27, 10.1681/ASN.2004080648 · DOI · Paper page
- Brighenti, 2014, Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer, Oncogene, 33, 4396, 10.1038/onc.2014.1 · DOI
- Burgdorf, 2011, Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans, PLoS One, 6, e15813, 10.1371/journal.pone.0015813 · DOI
- Cano, 2007, Pancreatic development and disease, Gastroenterology, 132, 745, 10.1053/j.gastro.2006.12.054 · DOI
- Chawla, 2010, Role of the renin angiotensin system in diabetic nephropathy, World J. Diabetes, 1, 141, 10.4239/wjd.v1.i5.141 · DOI
- Chen, 1993, Mapping of the p53 and mdm-2 interaction domains, Mol. Cell. Biol., 13, 4107, 10.1128/MCB.13.7.4107 · DOI · Paper page
- Cleary, 2009, Minireview: obesity and breast cancer: the estrogen connection, Endocrinology, 150, 2537, 10.1210/en.2009-0070 · DOI · Paper page
- Dai, 2004, Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5, J. Biol. Chem., 279, 44475, 10.1074/jbc.M403722200 · DOI · Paper page
- Di Cesare, 2001, Serum anti-p53 autoantibodies in patients with type 1 diabetes, Ann. Clin. Lab. Sci., 31, 253
- Donath, 2011, Type 2 diabetes as an inflammatory disease, Nat. Rev. Immunol., 11, 98, 10.1038/nri2925 · DOI · Paper page
- Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
- Doyle, S.L., Donohoe, C.L., Lysaght, J., Reynolds, J.V., 2012. Visceral obesity, metabolic syndrome, insulin resistance and cancer. The Proceedings of the Nutrition Society 71, 181-189. · DOI · Paper page
- Fomina-Yadlin, 2012, GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity, PLoS One, 7, e28808, 10.1371/journal.pone.0028808 · DOI
- Fujita, 2012, A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment, Exp. Anim./Jpn. Assoc. Lab. Anim. Sci., 61, 49, 10.1538/expanim.61.49 · DOI
- Glaser, 1994, Absence of PAX6 gene mutations in Gillespie syndrome (partial aniridia, cerebellar ataxia, and mental retardation), Genomics, 19, 145, 10.1006/geno.1994.1024 · DOI
- Gloria-Bottini, 2011, Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases, Diabetes Res. Clin. Pract., 91, e64, 10.1016/j.diabres.2010.11.031 · doi:10.1016/j.diabres.2010.11.031
- Grier, 2002, Conditional allele of mdm2 which encodes a p53 inhibitor, Genesis, 32, 145, 10.1002/gene.10066 · DOI
- He, 2014, AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity, Mol. Cell. Biol., 34, 148, 10.1128/MCB.00670-13 · DOI
- Hill, 2000, Pancreatic development and adult diabetes, Pediatr. Res., 48, 269, 10.1203/00006450-200009000-00002 · DOI
- Hilliard, 2011, Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching, Dev. Biol., 353, 354, 10.1016/j.ydbio.2011.03.017 · DOI
- Hoshino, A., Ariyoshi, M., Okawa, Y., Kaimoto, S., Uchihashi, M., Fukai, K., Iwai-Kanai, E., Ikeda, K., Ueyama, T., Ogata, T., Matoba, S., 2014. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. Proceedings of the National Academy of Sciences of the United States of America 111. pp. 3116–3121. · DOI · Paper page
- Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
- Jin, 2006, 14-3–3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation, EMBO J., 25, 1207, 10.1038/sj.emboj.7601010 · DOI
- Jonkers, 2001, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer, Nat. Genet., 29, 418, 10.1038/ng747 · DOI · Paper page
- Kaur, 2014, Rodent animal models: from mild to advanced stages of diabetic nephropathy, Inflammopharmacology, 22, 279, 10.1007/s10787-014-0215-y · DOI
- Kawai, 2007, RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity, Cancer Res., 67, 6026, 10.1158/0008-5472.CAN-07-1313 · DOI
- Kung, 2016, The P72R polymorphism of p53 Predisposes to obesity and metabolic dysfunction, Cell Rep., 14, 2413, 10.1016/j.celrep.2016.02.037 · DOI · Paper page
- Lane, 2010, p53 research: the past thirty years and the next thirty years, Cold Spring Harb. Perspect. Biol., 2, a000893, 10.1101/cshperspect.a000893 · DOI · Paper page
- Lim, 2013, Ribosomal S6 Kinase 2 (RSK2) maintains genomic stability by activating the Atm/p53-dependent DNA damage pathway, PLoS One, 8, e74334, 10.1371/journal.pone.0074334 · DOI
- Linke, 2008, Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans, Cell Death Differ., 15, 841, 10.1038/sj.cdd.4402309 · DOI · Paper page
- Mihailidou, 2015, Regulation of P21 during diabetes-associated stress of the endoplasmic reticulum, Endocr. Relat. Cancer, 22, 217, 10.1530/ERC-15-0018 · DOI
- Momand, 1992, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation, Cell, 69, 1237, 10.1016/0092-8674(92)90644-R · DOI · Paper page
- Nalabothula, 2010, The nucleolus takes control of protein trafficking Under cellular stress, Mol. Cell Pharm., 2, 203
- Nelson, 2013, 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology, Science, 342, 1094, 10.1126/science.1241908 · DOI · Paper page
- O'Dowd, 2013, Endocrine pancreatic development: impact of obesity and diet, Front. Physiol., 4, 170, 10.3389/fphys.2013.00170 · DOI
- Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
- Padgett, 2013, The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis, Ann. N.Y. Acad. Sci., 1281, 16, 10.1111/j.1749-6632.2012.06826.x · DOI · Paper page
- Park, J., Sarode, V.R., Euhus, D., Kittler, R., Scherer, P.E., 2012. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 109. pp. 21058–21063. · DOI · Paper page
- Ren, 2016, Permissive role of AMPK and autophagy in adiponectin deficiency-accentuated myocardial injury and inflammation in endotoxemia, J. Mol. Cell. Cardiol., 93, 18, 10.1016/j.yjmcc.2016.02.002 · DOI
- Ryu, 2014, Hyperglycemia as a risk factor for cancer progression, Diabetes Metab. J., 38, 330, 10.4093/dmj.2014.38.5.330 · DOI · Paper page
- Saran, 2015, US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States, Am. J. Kidney Dis.: Off. J. Natl. Kidney Found., 66, 10.1053/j.ajkd.2015.05.001 · DOI · Paper page
- Shadfan, 2012, MDM2 and MDMX: alone and together in regulation of p53, Transl. Cancer Res., 1, 88
- Shield, 2007, Neonatal diabetes: how research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life, Horm. Res., 67, 77
- Shikata, 2013, Diabetes mellitus and cancer risk: review of the epidemiological evidence, Cancer Sci., 104, 9, 10.1111/cas.12043 · DOI · Paper page
- Soler, 2012, New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy, Exp. Diabetes Res., 2012, 616313, 10.1155/2012/616313 · DOI
- Sun, 2007, 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction, J. Biol. Chem., 282, 8052, 10.1074/jbc.M610621200 · DOI · Paper page
- Takahashi, 2014, Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice, J. Diabetes Res., 2014, 590541, 10.1155/2014/590541 · DOI
- Tornovsky-Babeay, 2014, Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells, Cell Metab., 19, 109, 10.1016/j.cmet.2013.11.007 · DOI · Paper page
- Wang, 2012, Mdm2 and MdmX partner to regulate p53, FEBS Lett., 586, 1390, 10.1016/j.febslet.2012.02.049 · DOI
- Wellen, 2005, Inflammation, stress, and diabetes, J. Clin. Investig., 115, 1111, 10.1172/JCI25102 · DOI · Paper page
- Wilson, 2003, Gene expression cascades in pancreatic development, Mech. Dev., 120, 65, 10.1016/S0925-4773(02)00333-7 · DOI · Paper page
- Yao, 2013, Ultraviolet (UV) and hydrogen peroxide activate ceramide-ER stress-AMPK signaling axis to promote retinal pigment epithelium (RPE) cell apoptosis, Int. J. Mol. Sci., 14, 10355, 10.3390/ijms140510355 · DOI
- Zhang, 2003, Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway, Mol. Cell Biol., 23, 8902, 10.1128/MCB.23.23.8902-8912.2003 · DOI · Paper page
- Zhang, 2014, Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis, Dev. Biol., 396, 19, 10.1016/j.ydbio.2014.09.017 · DOI
- Zheng, 2005, Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function, Diabetes, 54, 1423, 10.2337/diabetes.54.5.1423 · DOI
Cited by
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Zhang, Y., Zeng, S. X., Hao, Q., & Lu, H.
- Venue
- Developmental Biology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 423
- Issue
- 1
- Pages
- 34-45
- ISSN
- 0012-1606
- Cited by
- 17
- References
- 16
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Funders
- NIH-NCI (R01 CA095441, R01CA172468, R01CA127724, R21CA190775, R21CA201889)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.